Expression of TNF-α protein in omental and subcutaneous adipose tissue in obesity

Diabetes Research and Clinical Practice

Volumn 79, Issue 2, 2008, Pages 214-219

  Cao, Yan Li ^a   Hu, Cui Zhu ^a   Meng, Xin ^a   Wang, Di Fei ^a   Zhang, Jin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Obesity; Omentum; Plasminogen activator inhibitor 1; Tumor necrosis factor alpha; Vascular diseases

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; OBESITY; OMENTUM; PERITONEAL BIOPSY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SUBCUTANEOUS FAT; WESTERN BLOTTING;

ADIPOSE TISSUE; ADULT; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; FEMALE; GASTROPLASTY; HUMANS; MALE; MIDDLE AGED; OBESITY; OMENTUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38349122149     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.08.030     Document Type: Article

References (23)

1. Cancello R., Tordjman J., Poitou C., Guilhem G., Bouillot J.L., Hugol D., et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55 (2006) 1554-1561
2. Sharma A.M. Adipose tissue: a mediator of cardiovascular risk. Int. J. Obes. Relat. Metab. Disord. 26 (2002) S5-S7
3. Ronti T., Lupattelli G., and Mannarino E. The endocrine function of adipose tissue: an update. Clin. Endocrinol. (Oxf.) 64 (2006) 355-365
4. Martens F.M., Rabelink T.J., Op't Roodt J., de Koning E.J., and Visseren F.L. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur. Heart J. 27 (2006) 1605-1609
5. Birgel M., Gottschling-Zeller H., Rohrig K., and Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1682-1687
6. Fearns C., Samad F., and Loskutoff D.J. Synthesis and localization of PAI-1 in the vessel wall. In: van Hinsbergh V.W.M. (Ed). Vascular Control of Hemostasis (1995), Harwood Academic Publishers, Amsterdam, The Netherlands 207-226
7. Juhan-Vague I., Alessi M.C., Mavri A., and Morange P.E. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J. Thromb. Haemost. 1 (2003) 1575-1579
8. Marcucci R., Brogi D., Sofi F., Giglioli C., Valente S., Liotta A.A., et al. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting. Heart 92 (2006) 377-381
9. Griffiths S.L., and Grainger D.J. Proposal of a novel diabetogenic mechanism involving the serpin PAI-1. Bioessays 28 (2006) 629-641
10. Sinkovic A., and Pogacar V. Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by troponin T and plasminogen-activator-inhibitor-1 (PAI-1). Thromb. Res. 114 (2004) 251-257
11. Chen C.M., Kong L.Z., Wen Z.M., Zhou B.F., Chen J.D., Li G.W., et al. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed. Env. Sci. 17 (2004) 1-36
12. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
13. Polak J., Klimcakova E., Moro C., Viguerie N., Berlan M., Hejnova J., et al. Effect of aerobic training on plasma levels and subcutaneous abdominal adipose tissue gene expression of adiponectin, leptin, interleukin 6, and tumor necrosis factor alpha in obese women. Metabolism 55 (2006) 1375-1381
14. Bougoulia M., Triantos A., and Koliakos G. Plasma interleukin-6 levels, glutathione peroxidase and isoprostane in obese women before and after weight loss. Association with cardiovascular risk factors. Hormones 5 (2006) 192-199
15. Matsuzawa Y., Shimomura I., Kihara S., and Funahashi T. Importance of adipocytokines in obesity-related diseases. Horm. Res. 60 (2003) 56-59
16. Ishikawa K., Takahashi K., Bujo H., Hashimoto N., Yagui K., and Saito Y. Subcutaneous fat modulates insulin sensitivity in mice by regulating TNF-alpha expression in visceral fat. Horm. Metab. Res. 38 (2006) 631-638
17. Kohler H.P., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 342 (2000) 1792-1801
18. Matsuzawa Y. White adipose tissue and cardiovascular disease. Best Pract. Res. Clin. Endocrinol. Metab. 19 (2005) 637-647
19. Karelis A.D., St-Pierre D.H., Conus F., Rabasa-Lhoret R., and Poehlman E.T. Metabolic and body composition factors in subgroups of obesity: what do we know?. J. Clin. Endocrinol. Metab. 89 (2004) 2569-2575
20. Lebovitz H.E., and Banerji M.A. Point: visceral adiposity is causally related to insulin resistance. Diab. Care 28 (2005) 2322-2325
21. von Eyben F.E., Mouritsen E., Holm J., Montvilas P., Dimcevski G., Suciu G., et al. Intra-abdominal obesity and metabolic risk factors: a study of young adults. Int. J. Obes. Relat. Metab. Disord. 27 (2003) 941-949
22. Wong S., Janssen I., and Ross R. Abdominal adipose tissue distribution and metabolic risk. Sports Med. 33 (2003) 709-726
23. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 3 (2006) 35-42